Partnering Agreements with Cephalon

Document Sample
Partnering Agreements with Cephalon Powered By Docstoc
					                                                          Business Report:




Partnering Agreements
with Cephalon 2010
Cephalon company profile
Company – therapy activity, partnering interests and partnering activity matrix
Marketed therapies
Pipeline therapies
Partnering interests
Partnering activities
Partnering contact listings
Key networking events
Cephalon partnering contracts

Publication date: January 2010
Report code: CP1089
Version: 3


www.currentpartnering.com
CurrentPartnering Reports.

CurrentPartnering provides industry executives with partnering best practice and essential business
intelligence. Further details about the range of services offered can be found at our website:

www.currentpartnering.com


This report edition was updated and published in January 2010.

The report was first published in July 2008.

For inquiries about the content of this report, please contact:

Email:              enquiry@currentpartnering.com

Telephone:          +44 (0)7896 656732

Fax:                +44 (0)8703 305993

Mail:               CurrentPartnering
                    Allanmere House
                    6 Hobgate
                    York
                    YO24 4HF
                    United Kingdom


All rights reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any
means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the
publisher, Wildwood Ventures Limited.

The facts in this report are believed to be correct at the time of publication but cannot be guaranteed.

Findings, conclusions and recommendations will be based on information gathered in good faith from both
primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such
Wildwood Ventures can accept no liability whatsoever for actions taken based on any information that may
subsequently prove to be incorrect.

© CurrentPartnering, a division of Wildwood Ventures Limited.

This report is a licensed product and is not to be photocopied.




© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.           CP1089      2


This report is a licensed product and is not to be photocopied.
Executive Summary
Welcome to the Partnering Agreements with Cephalon 2010.

The Partnering Agreements with Cephalon 2010 provides an in-depth insight into the partnering interests
and activity of one of the worlds leading biopharma companies.

One of the key aspects of partnering is finding those companies that are potential candidates for the
development and commercialization of the next generation of therapies. A lot of resources are spent on
finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the
company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma
companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers
between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of
2005-2009 according to reported deal size.

Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst
chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present
to discuss opportunities face to face.

Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and
pipeline products, partnering interests and partnering activity by therapeutic area.

The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything
required to assess the suitability of a company as a prospective partner. This includes a company overview,
detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering
activity according to deal type, phase of development, therapy area. The profile also includes in-depth
contact information for individuals within the business development function.

The company profile is also provided with a comprehensive listing of contract documents available in the
public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to
licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access
to each contract document on demand.

In summary, the report provides the user with the tools to make successful contact with the right bigpharma
partners effectively and efficiently:

     o    Detailed company profile
     o    In-depth marketed and pipeline activity
     o    Partnering interests statement and therapy focus
     o    Partnering activity for 2005-2009
               o Activity by deal type
               o Activity by phase of development
               o Activity by therapeutic area
               o List of recent partner companies
     o    Direct contact information for dealmaking executives
     o    General company and partnering contact information
     o    List of contract documents available to allow analysis of bigpharma deal terms


© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.                CP1089    3


This report is a licensed product and is not to be photocopied.
Each contract document is accessible through a link to an online version of the actual contract document as
filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment
of the following:

     o    What is actually granted by the agreement to the partner company?

     o    What exclusivity is granted?

     o    What is the payment structure for the deal?

     o    How are sales and payments audited?

     o    What is the deal term?

     o    How are the key terms of the agreement defined?

     o    How are IPRs handled and owned?

     o    Who is responsible for commercialization?

     o    Who is responsible for development, supply, and manufacture?

     o    How is confidentiality and publication managed?

     o    How are disputes to be resolved?

     o    Under what conditions can the deal be terminated?

     o    What happens when there is a change of ownership?

     o    What sublicensing and subscontracting provisions have been agreed?

     o    Which boilerplate clauses does the company insist upon?

     o    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

     o    Which jurisdiction does the company insist upon for agreement law?


This report is a part work and is also available as part of Partnering Agreements with Bigpharma report – see
the CurrentPartnering website for details – www.currentpartnering.com/reports.




© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.            CP1089   4


This report is a licensed product and is not to be photocopied.
TABLE OF CONTENTS

Executive Summary ........................................................................................................... 3

Chapter 1 – Introduction ................................................................................................... 8

Chapter 2 – Bigpharma top 50 and their dealmaking activity ...................................... 10

Chapter 3 – Most active bigpharma dealmakers ........................................................... 13

          3.1 Bigpharma M&A activity ............................................................................................................... 13
          3.2 Bigpharma partnering ................................................................................................................... 16

Chapter 4 – Top bigpharma deals by value ................................................................... 19
          4.1 Bigpharma M&A............................................................................................................................ 19
          4.2 Bigpharma partnering ................................................................................................................... 20

Chapter 5 – Submitting Opportunities to Bigpharma such as Cephalon.................... 25

          5.1 How to submit an opportunity ....................................................................................................... 25
          5.2 Opportunity submission template ................................................................................................. 26
          5.3 Sending emails ............................................................................................................................. 27
          5.4 Face to face at partnering events ................................................................................................. 28
          5.5 Online submission forms .............................................................................................................. 28

Chapter 6 – Forthcoming bigpharma partnering events .............................................. 29

          6.1 Forthcoming events ...................................................................................................................... 29

Chapter 7 – Cephalon – therapy locator ........................................................................ 30

          7.1 How to use the therapy matrix tables ........................................................................................... 30
          7.2 Therapeutic area definitions ......................................................................................................... 31
          7.3 Bigpharma – Therapeutic target matrix – marketed and pipeline compounds ............................. 33
          7.4 Bigpharma – Therapeutic target matrix – expressed partnering interests ................................... 34
          7.5 Bigpharma – Therapeutic target matrix – recent deals – 2005-2009 ........................................... 35

Chapter 8 –Company Profile – Cephalon....................................................................... 36

          8.1 How to use company profiles ....................................................................................................... 36
          8.2 Field definitions ............................................................................................................................. 37
          8.3 Cephalon company profile ............................................................................................................ 39

Chapter 9 – Resources .................................................................................................... 47

About CurrentPartnering................................................................................................. 48
© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.                                                      CP1089         5


This report is a licensed product and is not to be photocopied.
Recent titles from CurrentPartnering ............................................................................. 49

Order Form – Reports...................................................................................................... 52

Order Form – Partnering Agreements Company Profiles 2010 ................................... 53




© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.                      CP1089      6


This report is a licensed product and is not to be photocopied.
TABLE OF FIGURES
Figure 1: Bigpharma – top 50 by pharma sales .............................................................................................. 10
Figure 2: Leading Bigpharma M&A companies, 2005-2009............................................................................ 13
Figure 3: Bigpharma M&A activity – top 50 by pharma sales.......................................................................... 14
Figure 4: Leading Bigpharma partnering companies, 2005-2009 ................................................................... 16
Figure 5: Bigpharma partnering activity – top 50 by pharma sales ................................................................. 16
Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009 ....................................................... 19
Figure 7: Leading partnering deals by value, 2005-2009 ................................................................................ 21
Figure 8: Typical partnering opportunity submission template ........................................................................ 26
Figure 9: Therapeutic area definitions ............................................................................................................. 31
Figure 10: Therapeutic target matrix – marketed and pipeline compounds .................................................... 33
Figure 11: Therapeutic target matrix – expressed partnering interests ........................................................... 34
Figure 12: Therapeutic target matrix – recent deals 2005-2009 ..................................................................... 35
Figure 13: Company profile template and definitions used in report ............................................................... 37
Figure 14: Cephalon – Dealmaking frequency 2000-2009 .............................................................................. 41
Figure 15: Cephalon - recent deals (2005-2009) by deal type ........................................................................ 42
Figure 16: Cephalon - recent deals (2005 – 2009) by stage of development ................................................. 43
Figure 17: Cephalon – recent deals (2005 – 2009) by therapy area ............................................................... 43
Figure 18: Recent Cephalon partnering deals (2003-2009) where contract document available ................... 44
Figure 19: Online partnering resources ........................................................................................................... 47




© 2010 – CurrentPartnering, a division of Wildwood Ventures Limited. All rights reserved.                                              CP1089        7


This report is a licensed product and is not to be photocopied.
Chapter 1 – Introduction
The Partnering Agreements with Cephalon 2010 provides an in-depth insight into the dealmaking interests
and activity of one of the worlds leading fifty biopharma companies.

One of the key aspects of partnering is finding those companies that are potential candidates for the
development and commercialization of the next generation of therapies. A lot of resources are spent on
finding partners, identifying their interests and making contact to initiate discussions.

Best practice suggests that partnering is achieved through effective planning and execution of a partnering
strategy. First, determine what it is that a partnership is to achieve and prepare supporting materials. Identify
which parameters are to be used to assess a potential partner – global presence, R&D capability,
commercial success in therapy area, partnering track record, and so on. Second, identify and short list
prospective partners capable of delivering on these needs. Third, initiate contact with named individuals face
to face or by telephone, using email as a means of exchanging information. Fourth, follow up initial contact to
develop a relationship that determines interest in the opportunity and lays the foundations for future contact
should new opportunities arise.

Generally, it is appropriate to short list up to ten companies for initial contact, with an additional five to ten in
reserve. Managing concurrent discussions allow the presence of contingency partners should the lead
partner(s) decline interest in the opportunity. In addition, should more than one company express interest to
the point of entering negotiations, it is preferable to have several companies completing to partnering the
opportunity. This not only pushes up the price, but more importantly allows the company to get the best deal
overall.

Best practice has shown that deals are generally done between people, rather than companies. What is
meant by this is that individuals are the driving force behind a deal. Therefore, the development of
relationships is critical for a successful partnership. This is why it is recommended that contact is made via
the telephone or face to face, so that the licensor is speaking directly to the licensee.

Business development executives in bigpharma expect to speak to their counterparts, so direct contact is the
most effective way of relationship building, understanding a companies needs, and getting an opportunity
reviewed.


This report provides the tools to enable effective and efficient partnering with one of bigpharma’s top fifty
companies.

In the first instance, the report provides a comprehensive overview of the company’s business activity, and
partnering interests and activity.

Short listing of the company as a prospective partner is achieved through the analysis of the company
profile. The profile provides an in-depth analysis of a company’s business activity, therapeutic marketing
capabilities, pipeline development expertise, as well as detailed partnering activity and interests.

Once a short list of prospective partners is drafted, detailed contact information for business development
executives in the compan
				
DOCUMENT INFO
Description: Using this report, dealmakers will effectively and efficiently determine the suitablility of Cephalon as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners. The report provides a firm basis for initial due diligence into Servier as a prospective partner company. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size. Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face. Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area. The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function. The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-p
BUY THIS DOCUMENT NOW PRICE: $495 100% MONEY BACK GUARANTEED
PARTNER Current Partnering
CurrentPartnering is the partnering best practice and report publishing arm of Wildwood Ventures Ltd. CurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers.